The role of estrogen receptor in melanoma

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 12, 2007, Pages 1639-1648

  Tanemura, Atsushi ^a   van Hoesel, Anneke Q ^a   Mori, Takuji ^a   Yu, Terrance ^a   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

17 estradiol; Estrogen receptor; Melanoma; Promoter hypermethylation

Indexed keywords

CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; DNA FRAGMENT; ESTROGEN RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; SOMATOMEDIN RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DISEASE MARKER; DNA METHYLATION; DNA SEQUENCE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOMETRIUM CANCER; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MELANOMA; MONOTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER;

ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 37349062738     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.12.1639     Document Type: Review

References (57)

1. JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J, THUN MJ: Cancer statistics, 2007. CA Cancer J. Clin. (2007) 57:43-66.
2. FRANCESCHI S, BARON AE, LA VECCHIA C: The influence of female hormones on malignant melanoma. Tumori (1990) 76:439-449.
3. LENS MB, EISEN TG: Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin. Pharmacother. (2003) 4:2205-2211.
4. BODENHAM DC, HALE B: Malignant melanoma. Endocrine Therapy in Malignant Disease. Edited by London, Saunders WB, Co., Ltd. (1972):377-383.
5. DEVITA VT Jr, FISHER RI: Natural history of malignant melanoma as related to therapy. Cancer Treat. Rep. (1976) 60:153-157.
6. HOUGHTON AN, FLANNERY J, VIOLA MV: Malignant melanoma of the skin occurring during pregnancy; Cancer (1981) 48:407-410.
7. SUTHERLAND CM, LOUTFI A, MATHER FJ, CARTER RD, KREMENTZ ET: Effect of pregnancy upon malignant melanoma. Surg. Gynecol. Obstet. (1983) 157:443-446.
8. SMITH MA, FINE JA, BARNHILL RL, BERWICK M: Hormonal and reproductive influences and risk of melanoma in women. Int. J. Epidermiol. (1998) 27:751-757.
9. SILIPO V, DE SIMONE P, MARIANI G, BUCCINI P, FERRARI A, CATRICALA C: Malignant melanoma and pregnancy; Melanoma Res. (2006) 16:497-500.
10. LENS MB, ROSDAHL I, AHLBOM A et al.: Effect of pregnancy on survival in women with cutaneous malignant melanoma. J. Clin. Oncol. (2004) 22:4369-4375.
11. GRIN CM, DRISCOLL MS, GRANT-KELS JM: The relationship of pregnancy; hormones, and melanoma. Semin. Cutan. Med. Stag. (1998) 17:167-171.
12. ROSE C, PEDERSEN L, MOURIDSEN HT: Endocrine treatment with anti-estrogen, anti-androgen or progestagen of advanced malignant melanoma: three consecutive Phase II trials. Eur. J. Cancer Clin. Oncol. (1985) 21:1171-1174.
13. FISHER RI, NEIFELD JP, LIPPMAN ME: Oestrogen receptors in human malignant melanoma. Lancet (1976) 2:337-339.
14. SPEIRS V, CARDER PJ, LANE S, DODWELL D, LANSDOWN MR, HANBY AM: Oestrogen receptor β: what it means for patients with breast cancer. Lancet Oncol. (2004) 5:174-181.
15. PETTERSSON K, GUSTAFSSON JA: Role of estrogen receptor β in estrogen action. Annu. Rev. Physiol. (2001) 63:165-192.
16. YAGER JD, DAVIDSON NE: Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. (2006) 354:270-282.
17. ZHANG D, TRUDEAU VL: Integration of membrane and nuclear estrogen receptor signaling. Comp. Biochem. Physiol. A Mol. Integr. Physiol. (2006) 144:306-315.
18. SHAO W, BROWN M: Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy; Breast Cancer Res. (2004) 6:39-52.
19. PEDRAM A, RAZANDI M, WALLACE DC, LEVIN ER: Functional estrogen receptors in the mitochondria of breast cancer cells. Mol. Biol. Cell (2006) 17:2125-2137.
20. COUSE JF, LINDZEY J, GRANDIEN K, GUSTAFSSON JA, KORACH KS: Tissue distribution and quantitative analysis of estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) messenger ribonucleic acid in the wild-type and ERβ-knockout mouse. Endocrinology (1997) 138:4613-4621.
21. OSBORNE CK: Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. (1998) 51:227-238.
22. BEATSON G: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment. Lancet (1896) 2:104-107.
23. Tamoxifen for early breast cancer: an overview of the randomised trials. Early breast cancer trialists' collaborative group. Lancet (1998) 351:1451-1467.
24. CUNAT S, HOFFMANN P, PUJOL P: Estrogens and epithelial ovarian cancer. Gynecol. Oncol. (2004) 94:25-32.
25. SHANG Y: Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat. Rev. Cancer (2006) 6:360-368.
26. CARRUBA G: Estrogens and mechanisms of prostate cancer progression. Ann. NY Acad. Sci. (2006) 1089:201-217.
27. DI LEO A, MESSA C, CAVALLINI A, LINSALATA M: Estrogens and colorectal cancer. Curr. Drug Targets Immune Endocr. Metabol. Disord. (2001) 1:1-12.
28. WALKER MJ, BEATTIE CW, PATEL MK, RONAN SM, DAS GUPTA TK: Estrogen receptor in malignant melanoma. J. Clin. Oncol. (1987) 5:1256-1261.
29. COHEN C, DEROSE PB, CAMPBELL WG, SCHLOSNAGLE DC, SGOUTAS D: Estrogen receptor status in malignant melanoma. Am. J. Dermatopathol. (1990) 12:562-564.
30. SCHMIDT AN, NANNEY LB, BOYD AS, KING LE Jr, ELLIS DL: Oestrogen receptor-β expression in melanocytic lesions. Exp. Dermatol. (2006) 15:971-980.
31. SINGH MN, STRINGFELLOW HF, PARASKEVAIDIS E, MARTIN-HIRSCH PL, MARTIN FL: Tamoxifen: important considerations of a multi-functional compound with organ-specific properties. Cancer Treat. Rev. (2007) 33:91-100.
32. GELMANN EP: Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin. Oncol. (1997) 24(S1):65-70.
33. JONES JA, ALBRIGHT KD, CHRISTEN RD, HOWELL SB, MCCLAY EF: Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites. Cancer Res. (1997) 57:2657-2660.
34. CREAGAN ET, INGLE JN, GREEN SJ, AHMANN DL, JIANG NS: Phase II study of tamoxifen in patients with disseminated malignant melanoma. Cancer Treat. Rep. (1980) 64:199-201.
35. LENS MB, REIMAN T, HUSAIN AF: Use of tamoxifen in the treatment of malignant melanoma. Cancer (2003) 98: 1355-1361.
36. COCCONI G, BELLA M, CALABRESI F et al.: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N. Engl. J. Med. (1992) 327:516-523.
37. O'DAY SJ, GAMMON G, BOASBERG PD et al.: Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2. Granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J. Clin. Oncol. (1999) 17:2752-2761.
38. PLANTELLI M, MAGGIANO N, RICCI R et al.: Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J. Invest. Dermatol. (1995) 105:248-253.
39. PIANTELLI M, RANELLETTI FO, MAGGIANO N: Tamoxifen and Quercetin in melanoma cell growth. role of type II estrogen binding sites. Maio M (Ed.), IOS Press, Amsterdam, The Netherlands (1996):248-253.
40. LAMA C, ANGELUCCI C, BRUZZESEN et al.: Sensitivity of human melanoma cells to oestrogens, tamoxifen and quercetin: is there any relationship with type I and II oestrogen binding site expression? Melanoma Res. (1998) 8:313-322.
41. KANDA N, WATANABE S: 17β-estradiol, progesterone, and dihydrotestosterone suppress the growth of human melanoma by inhibiting interleukin-8 production. J. Invest. Dermatol. (2001) 117:274-283.
42. KANTER-LEWENSOHN L, GIRNITA L, GIRNITA A et al.: Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Mol Cell Endocrinol. (2000) 165:131-137.
43. HERMAN JG, BAYLIN SB: Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. (2003) 349:2042-2054.
44. HOON DS, SPUGNARDI M, KUO C, HUANG SK, MORTON DL, TABACK B: Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 23:4014-4022.
45. ISSA JP, OTTAVIANO YL, CELANO P, HAMILTON SR, DAVIDSON NE, BAYLIN SB: Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet. (1994) 7:536-540.
46. FUJII S, TOMINAGA K, KITAJIMA K et al.: Methylation of the oestrogen receptor gene in non-neoplastic epithelium as a marker of colorectal neoplasia risk in longstanding and extensive ulcerative colitis. Gut (2005) 54:1287-1292.
47. OTTAVIANO YL, ISSA JP, PARL FF, SMITH HS, BAYLIN SB, DAVIDSON NE: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. (1994) 54:2552-2555.
48. MORI T, MARTINEZ SR, O'DAY SJ et al.: Estrogen receptor-α methylation predicts melanoma progression. Cancer Res. (2006) 66:6692-6698.
49. GIACINTI L, CLAUDIO PP, LOPEZ M, GIORDANO A: Epigenetic information and estrogen receptor α expression in breast cancer. Oncologist (2006) 11:1-8.
50. FERGUSON AT, LAPIDUS RG, BAYLIN SB, DAVIDSON NE: Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. (1995) 55:2279-2283.
51. YANG X, FERGUSON AT, NASS SJ et al.: Transcriptional activation of estrogen receptor α in human breast cancer cells by histone deacetylase inhibition. Cancer Res. (2000) 60:6890-6894.
52. LEADER JE, WANG C, FU M, PESTELL RG: Epigenetic regulation of nuclear steroid receptors. Biochem. Pharmacol. (2006) 72:1589-1596.
53. YANG X, PHILLIPS DL, FERGUSON AT, NELSON WG, HERMAN JG, DAVIDSON NE: Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res. (2001) 61:7025-7029.
54. MUNSTER P, MARCHION D, BICAKU E et al.: Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol. (2007) 25:1979-1985.
55. DAUD A, SCHMITT M, MARCHION D et al.: Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies. Am. Soc. Clin. Oncol. (2007) 25:3502.
56. TABACK B, HOON DS: Circulating nucleic acids in plasma and serum: past, present and future. Curr. Opin. Mol. Ther. (2004) 6:273-278.
57. JIANG SY, JORDAN VC: Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J. Natl. Cancer Inst. (1992) 84:580-591.